Neumora Therapeutics, Inc. Expected to Earn Q3 2024 Earnings of ($0.33) Per Share (NASDAQ:NMRA)

Neumora Therapeutics, Inc. (NASDAQ:NMRA) – Investment analysts at HC Wainwright issued their Q3 2024 earnings per share estimates for Neumora Therapeutics in a report released on Tuesday, October 1st. HC Wainwright analyst D. Tsao anticipates that the company will earn ($0.33) per share for the quarter. HC Wainwright has a “Buy” rating and a $30.00 price target on the stock. The consensus estimate for Neumora Therapeutics’ current full-year earnings is ($1.51) per share. HC Wainwright also issued estimates for Neumora Therapeutics’ Q4 2024 earnings at ($0.33) EPS, FY2024 earnings at ($1.37) EPS, FY2025 earnings at ($1.32) EPS, FY2026 earnings at ($1.40) EPS, FY2027 earnings at ($0.99) EPS and FY2028 earnings at $0.40 EPS.

Neumora Therapeutics (NASDAQ:NMRA) last issued its quarterly earnings results on Tuesday, August 6th. The company reported ($0.37) EPS for the quarter, meeting analysts’ consensus estimates of ($0.37).

Other research analysts also recently issued research reports about the company. Mizuho began coverage on Neumora Therapeutics in a report on Monday, July 8th. They set an “outperform” rating and a $20.00 target price on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and set a $29.00 target price on shares of Neumora Therapeutics in a report on Wednesday, September 4th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 target price on shares of Neumora Therapeutics in a report on Thursday, September 12th. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, Neumora Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $22.90.

Neumora Therapeutics Price Performance

Shares of NMRA opened at $14.76 on Thursday. The stock has a 50-day moving average price of $12.03 and a 200 day moving average price of $11.21. Neumora Therapeutics has a one year low of $8.33 and a one year high of $21.00.

Insider Transactions at Neumora Therapeutics

In other news, CFO Joshua Pinto sold 31,642 shares of the stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $11.78, for a total transaction of $372,742.76. Following the sale, the chief financial officer now directly owns 154,658 shares in the company, valued at approximately $1,821,871.24. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CFO Joshua Pinto sold 31,642 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $11.78, for a total value of $372,742.76. Following the sale, the chief financial officer now directly owns 154,658 shares in the company, valued at $1,821,871.24. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Robert A. Lenz sold 30,788 shares of the firm’s stock in a transaction that occurred on Tuesday, September 17th. The shares were sold at an average price of $11.81, for a total value of $363,606.28. Following the completion of the sale, the insider now owns 339,205 shares in the company, valued at approximately $4,006,011.05. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 90,926 shares of company stock worth $1,067,758. 26.40% of the stock is currently owned by company insiders.

Institutional Trading of Neumora Therapeutics

Large investors have recently added to or reduced their stakes in the business. Avidity Partners Management LP increased its position in Neumora Therapeutics by 10.6% in the 4th quarter. Avidity Partners Management LP now owns 1,990,632 shares of the company’s stock valued at $33,940,000 after acquiring an additional 190,632 shares during the period. Price T Rowe Associates Inc. MD acquired a new position in shares of Neumora Therapeutics during the 1st quarter valued at $10,354,000. Callan Capital LLC increased its position in shares of Neumora Therapeutics by 222.6% during the 2nd quarter. Callan Capital LLC now owns 661,194 shares of the company’s stock valued at $6,500,000 after purchasing an additional 456,207 shares during the period. Rhumbline Advisers increased its position in shares of Neumora Therapeutics by 488.3% during the 2nd quarter. Rhumbline Advisers now owns 103,258 shares of the company’s stock valued at $1,015,000 after purchasing an additional 85,706 shares during the period. Finally, SG Americas Securities LLC acquired a new position in shares of Neumora Therapeutics during the 2nd quarter valued at $566,000. 47.65% of the stock is currently owned by institutional investors and hedge funds.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.